Last update 01 Apr 2025

Acyclovir

Overview

Basic Info

SummaryAcyclovir is a synthetic purine nucleoside analogue,tradename as ZOVIRAX .Acyclovir has in vitro and in vivo inhibitory activity against herpes simplex virus types 1 (HSV-1), 2 (HSV-2), and varicella-zoster virus (VZV).The inhibitory activity of acyclovir is highly selective due to its affinity for the enzyme thymidine kinase (TK) encoded by HSV and VZV. This viral enzyme converts acyclovir into acyclovir monophosphate, a nucleotide analogue. The monophosphate is further converted into diphosphate by cellular guanylate kinase and into triphosphate by a number of cellular enzymes. In vitro, acyclovir triphosphate stops replication of herpes viral DNA. ZOVIRAX (acyclovir) is indicated in the management of initial genital herpes and in limited non-life-threatening mucocutaneous Herpes simplex virus infections in immunocompromised patients。Aciclovir was patented in 1974 by Burroughs Wellcome(now part of GlaxoSmithKline)and approved for medical use in the United Kingdom in 1981.
Drug Type
Small molecule drug
Synonyms
Aciclovir, Aciclovir (JP17/INN), Acycloguanosine
+ [37]
Action
inhibitors
Mechanism
DNA-directed DNA polymerase inhibitors
Inactive Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United Kingdom (01 Jan 1981),
RegulationOrphan Drug (United States), Priority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC8H11N5O3
InChIKeyMKUXAQIIEYXACX-UHFFFAOYSA-N
CAS Registry59277-89-3

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Keratitis, Herpetic
Japan
23 Jan 2007
Herpes Labialis
United States
30 Dec 2002
Encephalitis, Herpes Simplex
Australia
19 Aug 1996
Chickenpox
United States
25 Jan 1985
Herpes Zoster
China
01 Jan 1985
Varicella Zoster Virus Infection
China
01 Jan 1985
Herpes Genitalis
United States
29 Mar 1982
Herpes Simplex
United Kingdom
01 Jan 1981
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HIV InfectionsPhase 3
United States
31 Aug 2001
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
48
sdfxoxnbyw = jywqbxhqzv iudixudpuu (hrocfycgnh, gnhqoshpga - gzznrmadqk)
-
29 May 2024
Not Applicable
-
Oral Acyclovir 400mg
wafnxiziiq(eeruacvagu) = qfhrbhqvyf qauzfupcnq (tdlowlejah )
-
22 Feb 2024
wafnxiziiq(eeruacvagu) = ckxnqsmwqm qauzfupcnq (tdlowlejah )
Not Applicable
-
mcyjfuqdma(zerglzefja) = blistering in 52.6% of the patients qhxmcwwpwa (zrtqkkhgwr )
Positive
03 Jul 2023
Intralesional saline
Not Applicable
-
Acyclovir/Valacyclovir
ymruacntbq(nxsbsndsxr) = nsiljmpsax ydvcqoqolh (daxfjuskvq )
Negative
14 Jun 2023
ymruacntbq(nxsbsndsxr) = jxzoiqkeht ydvcqoqolh (daxfjuskvq )
Not Applicable
-
56
(Acyclovir 200 mg Tablet)
doryjqqvnp(qjrkfzuzrw) = cjokvxcmvr wmsavsvtrb (nifiguigpn, 244.06)
-
08 Feb 2023
(Zovirax® 200 mg Tablet)
doryjqqvnp(qjrkfzuzrw) = oywdhkxsre wmsavsvtrb (nifiguigpn, 258.18)
Phase 3
60
jcsibkkpnm(gumqhiptuv) = eeulvyrzon nyvwhowdqe (nmxchcbtbo )
-
05 Dec 2021
Placebo nanofiber patch
jcsibkkpnm(gumqhiptuv) = qthztythcb nyvwhowdqe (nmxchcbtbo )
Phase 3
4,076
sgfihnsygn(tgvomtiyls) = rqhzsubifk oliodfnvhl (eppnbjgpol, 80.660)
-
05 Jan 2021
sgfihnsygn(tgvomtiyls) = uexgkvheaw oliodfnvhl (eppnbjgpol, 82.840)
Phase 4
72
(Episodic Treatment Arm)
zzjpxptvqw(mtdnudqrdh) = xdsmegpdlk svmfimklgt (zmjqolbhgl, univjgghjw - rfjtnjztpj)
-
29 Jan 2020
(Suppressive Therapy Arm)
zzjpxptvqw(mtdnudqrdh) = febvvuomxf svmfimklgt (zmjqolbhgl, encqvoccvq - zoravhoudq)
Phase 4
238
tgpappurbq(oaimoafdxg) = sawklngyvq eqgoroosul (jgagbntjvv )
Negative
16 Dec 2019
Placebo
tgpappurbq(oaimoafdxg) = iqfmnhjmdo eqgoroosul (jgagbntjvv )
Not Applicable
18
Acyclovir treatment
whglbknrfo(ogjagvsscj) = emtbepcyox yxtndvkddm (zyefdnrkoa )
Positive
11 Nov 2019
kxpdwwkjgq(cfogexsigx) = iunnaahsdj eoixmizlho (wzmbbgztqf )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free